I ron is an essential trace element which plays an important role in the catalysis of oxidative reactions and in the transport of soluble gases (1) . Assessment of iron stores is done routinely in everyday nephrology practice (2) , through measurement of total iron saturation (ISAT; also known as transferrin saturation) and serum ferritin (3) .
Iron deficiency is common in patients with nondialysis-dependent chronic kidney disease (NDD-CKD) (4, 5) , but it is unclear to what extent levels of ISAT and ferritin are associated with outcomes in this population. Examining hard endpoints is especially important given the concern that exceeding certain limits of ISAT or ferritin may be deleterious through excess iron deposition and induction of oxidative stress (6 -9) . We examined the associations of these iron markers with all-cause mortality, the composite of predialysis mortality or ESRD, and the slopes of estimated GFR (eGFR) in 453 men with moderate and advanced NDD-CKD.
Materials and Methods
The study population consisted of 1012 patients evaluated for NDD-CKD at Salem Veteran Affairs Medical Center (VAMC) between January 1, 1990 , and June 30, 2005, and followed until April 1, 2007 . Four hundred and sixty-one patients (46%) had both ISAT and ferritin measurements available for analyses. Five women and three patients whose race was not white or black were excluded; the final study population consisted of 453 patients.
Baseline characteristics were recorded retrospectively as measured at the time when iron stores were assessed, as detailed elsewhere (10, 11) . Use of commonly prescribed medications [aspirin, angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), statins, and activated vitamin D products] was assessed over the entire follow-up period and used as surrogate markers for quality of clinical care. Serum creatinine levels were recorded longitudinally for estimation of slopes. GFR was estimated using the abbreviated equation developed for the Modification of Diet in Renal Disease Study (12) . Serum iron, transferrin, and ferritin were measured in a single laboratory. Serum iron was measured by a timed endpoint method [reference range: 49 to 181 g/dl, coefficient of variation (CV): 4%], and transferrin was measured by a turbidimetric method (180 to 329 mg/dl, CV: 2.5%), both by using a Beckman Coulter LXI autoanalyzer (Beckman, Fullerton, California). Serum ferritin was measured by an immunoenzymatic method (22 to 322 ng/ml, CV: 5.5%) using a Beckman Coulter Access2 autoanalyzer (Beckman, Fullerton, Cal-ifornia). ISAT was calculated as serum iron/total iron binding capacity (TIBC) ϫ 100%.
Statistical Analyses
Both serum ISAT and ferritin showed skewed distributions; hence, they were transformed to their natural logarithms. Because 90% of patients had an ISAT of Ͻ30% with normal distribution in this range, all analyses were performed on the entire sample and then repeated separately on the subset with ISAT Ͻ30%. Because the level of ISAT can be affected by changes in both serum iron and TIBC, analyses were repeated using separately these two variables as predictors. Missing data points for comorbidity index (0.3% missing), 24-h urine protein (3% missing) and white blood cell count (WBC, 3% missing) were imputed using linear regression with all other patient characteristics serving as independent variables. ISAT and ferritin were analyzed both as log-transformed continuous variables and as categorical measures after dividing them into quartiles. Patients were also grouped based on the cutoff levels of ISAT Ն15% (approximately corresponding to the median value of ISAT and also the level regarded as a threshold of absolute iron deficiency (13, 14) ) and ferritin Ն100 ng/ml [approximately corresponding to the median value of serum ferritin and the lower limit of desirable therapeutic target in CKD patients treated with erythropoiesis stimulating agents (ESAs) according to Kidney Disease Outcomes Quality Initiative guidelines (2) ].
The starting time for survival analysis was the date of the first encounter in the Nephrology Clinic at Salem VAMC. Outcome measures were all-cause mortality and the composite of predialysis allcause mortality or ESRD. Patients were considered lost to follow-up if no contact was documented with them for more than 6 mo, and they were censored at the date of the last documented contact. Cox models were used to adjust for the effect of confounders. Selection of variables to be included in multivariable models was performed by a multivariable regression spline function using backward elimination of weak predictors using a closed test approach (15) . Age, race, comorbidity index, eGFR, albumin, hemoglobin, and WBC were forced in the models. Nonlinear associations were examined by including polynomial terms and by using restricted cubic splines; analyses were restricted to values above the fifth and below the 95th percentile of the predictor variable to maintain the stability of the spline models.
Progression of CKD was assessed by examining slopes of eGFR in mixed-effects models allowing for a random intercept and slope. The change in eGFR from baseline until death, start of dialysis, or loss of follow-up (whichever occurred first) was studied by building a multilevel model for change (16) .
Subgroup analyses were performed in groups divided by median values of eGFR, albumin, hemoglobin, comorbidity index, WBC, and proteinuria. P values of less than 0.05 were considered significant. Statistical analyses were performed using STATA statistical software version 10 (STATA Corporation, College Station, Texas). The Research and Development Committee at the Salem VAMC approved the study protocol.
Results
The mean age of the cohort was 69 Ϯ 10 yr, 26% were black, and the mean eGFR was 33 Ϯ 14 ml/min/1.73m 2 . Two-hundred fifty-nine patients died [mortality rate: 156/1000 patientyears, 95% confidence interval (CI): 138 to 176] and 125 patients initiated dialysis (dialysis initiation rate: 94/1000 patient-years, 95% CI: 79 to 112) during a median follow-up of 3 yr. Eight patients were lost to follow-up; their characteristics were not significantly different (data not shown).
ISAT
The frequency distribution of serum ISAT is shown in Figure  1 . Baseline characteristics in patients divided by quartiles of ISAT are shown in Table 1 . Patients with higher ISAT were more likely to be diabetic, but less likely to have cardiovascular disease, had higher hemoglobin and ferritin, and lower comorbidity index and WBC. Serum iron concentrations were higher, but TIBC levels were lower in patients with higher ISAT. The frequency of medication use was identical in different ISAT quartiles except for ACEI/ARB, which were less likely to be prescribed to patients in the lowest ISAT quartile.
After adjustment for age, race, comorbidity index, eGFR, hemoglobin, albumin, and WBC, compared with patients with ISAT of 18 to 23%, patients with ISAT of Ͻ12%, 13 to 17%, and Ͼ23% had hazard ratios (95% CI) of all-cause mortality of 1.40 (0.99 to 1.98), 1.20 (0.82 to 1.76), and 0.97 (0.67 to 1.41), P for trend was 0.025. Lower log-ISAT was associated with higher mortality both overall ( Figure 2 ) and in patients with ISAT Ͻ30% (data not shown). There was no interaction with comorbidity index, eGFR, hemoglobin, serum albumin, WBC, or proteinuria. The association between serum iron and mortality was similar to that seen for ISAT; however, TIBC was not associated with mortality. ISAT was not associated with the composite outcome of predialysis mortality or ESRD (data not shown).
In mixed-effects models examining slopes of eGFR, each Figure 3 . Excluding patients with ISAT Ͼ30% from analyses rendered the association between ISAT and eGFR slopes nonsignificant; a 10% higher ISAT was associated with a 0.38 ml/min/1.73m 2 /yr lower slope of eGFR (95% CI: Ϫ1.14, 0.34), P ϭ 0.3. An interaction with albumin and WBC was present, in that the associations were only significant in subgroups with lower albumin and with higher WBC. Both higher serum iron and lower TIBC were associated with a trend toward steeper slopes of eGFR.
Serum Ferritin
Serum ferritin displayed skewed distribution, as shown in Figure 1 . Baseline characteristics in patients divided by quartiles of serum ferritin are shown in Table 2 . Patients with higher ferritin were younger, more likely to be black, less likely to have cardiovascular disease, and had lower serum albumin and higher proteinuria. ISAT levels were higher and TIBC levels were lower in patients with higher ferritin; serum iron, hemoglobin, and eGFR, on the other hand, were not significantly different across ferritin quartiles. The frequency of medication use was similar across different ferritin quartiles.
After adjustment for age, race, comorbidity index, cardiovascular disease, eGFR, hemoglobin, albumin, WBC, and protein-uria, relative to patients with ferritin of Ͻ60 ng/ml, those with ferritin levels of 60 to 130, 131 to 250, and Ͼ250 ng/ml had a hazard ratio (95% CI) of mortality of 1.33 (0.93 to 1.90), 0.87 (0.60 to 1.28), and 1.42 (0.98 to 2.05), P ϭ 0.3 for trend. The association between ferritin and mortality was nonlinear (Figure 4 ; joint significance of polynomial terms of log-ferritin: P ϭ 0.06) with a trend toward higher mortality seen in patients with ferritin Ͼ250 ng/ml (corresponding to log-ferritin of Ͼ5.5 ng/ ml). The association between ferritin and mortality showed a similar pattern in the subgroup of patients with eGFR Ͻ30 ml/min/1.73m 2 and with a comorbidity index Ͼ2, but not in those with eGFR Ն30 ml/min/1.73m 2 and with a comorbidity index Յ2. There were no other interactions. The association between ferritin and the combined endpoint was similar to associations with all-cause mortality. There was also no significant association between ferritin and the slope of eGFR: one log-unit higher ferritin level was associated with a multivariable adjusted slope (95% CI) of Ϫ0.19 ml/min/1.73m 2 /yr (Ϫ0.66, 0.27), P ϭ 0.4.
Concomitant ISAT and Ferritin
As shown in Figure 5 , compared with the group with ISAT Ն15% and ferritin Ն100 ng/ml, a higher mortality was associated with ISAT Ͻ15% and ferritin Ն100 ng/ml, and with ISAT Ͻ15% and ferritin Ͻ100 ng/ml. Mortality was not significantly different in patients with ISAT Ն15% and ferritin Ͻ100 ng/ml. These associations were similar in all examined subgroups. There was no significant difference in the composite outcome of predialysis mortality or ESRD and in the slopes of eGFR between the four categories (data not shown).
Discussion
We found higher all-cause mortality associated with lower serum ISAT levels, independent of serum ferritin in NDD-CKD patients. Because mortality was similar in the two highest quartiles of ISAT, we applied cubic splines to more precisely characterize a potential nonlinear association and found higher mortality with ISAT levels below approximately 25% (log-ISAT of 3.25, Figure 1) . A trend for higher mortality was observed in patients with serum ferritin values Ͼ250 ng/ml, especially in those with more advanced stages of CKD. The slopes of eGFR were steeper in patients with higher ISAT, but this finding was restricted to subgroups of patients with lower serum albumin or higher WBC, indicating an interaction with malnutrition and inflammation.
Serum ISAT and ferritin concentrations are often applied in clinical practice as markers of bodily iron stores, but their sensitivity and specificity as diagnostic tools have been shown to be limited (3, 17, 18) . Both serum ferritin and the two components of ISAT (serum iron concentration and TIBC) are affected by numerous non-iron-related physiologic and pathologic conditions (19, 20) . Inflammation especially can result in higher serum ferritin levels (21) (22) (23) . The complexity of interpreting ISAT and ferritin is illustrated in the baseline characteristics of our patients with different levels of these markers: higher ISAT was associated with higher serum iron and hemoglobin concentrations (indicating higher iron stores), but also with lower TIBC (indicating potentially the confounding presence of malnutrition and/or inflammation; Table 1 ). Similarly, higher ferritin concentrations were associated with significantly higher ISAT levels, but this association was solely due to the lower TIBC associated with higher ferritin levels ( Table 2 ), suggesting that inflammation may be a more important determinant of higher serum ferritin concentrations, and questioning the role of elevated ferritin as a useful marker of adequate or elevated iron stores. These considerations could explain the higher mortality seen with higher ferritin, which could be ascribed to the confounding effect of chronic inflammation.
The higher sensitivity of a low ISAT as a diagnostic marker of iron deficiency (3, 17) makes it more likely that the robust association between low ISAT and higher mortality in our study could be related to lower iron stores. Iron-containing enzymes participate in catalysis of oxidation reactions and in transport of several soluble gases, and adequate iron stores are indispensable for erythropoiesis, making an association between lower iron stores and higher mortality physiologically plausible. To the best of our knowledge, our study is the first one to examine the association between markers of iron stores and mortality in NDD-CKD. However, more detailed observational studies and prospective clinical trials will be needed to fully characterize the nature of such an association.
We also found more significant progression of CKD (steeper slopes of eGFR) in patients with higher ISAT. These results seemed to be driven mostly by the small fraction of our patient population with ISAT Ͼ30%; the smaller number of patients in this ISAT range and the uncertainty of the meaning of a higher ISAT in them (vide supra) make the interpretation of our finding difficult. Possible mechanisms whereby truly higher iron levels could be deleterious to the kidney function include the engenderment of oxidative stress and parenchymal iron deposition with subsequent tissue damage, (24,25) but one would expect to also find an effect on mortality from such a mechanism, which we did not. Conversely, the lower TIBC seen in patients with higher ISAT, the fact that the association between higher ISAT and progression of CKD was limited to subgroups with lower albumin and higher WBC, and that lower TIBC in itself showed a trend toward an association with a steeper slope of eGFR indicates that chronic inflammation (which has been linked to more significant progression of CKD in earlier studies (26,27)) could also have affected these outcomes. The concept that higher serum iron levels may be linked to lower mortality, but also more progression of kidney disease in patients with NDD-CKD, will have to be tested in prospective clinical trials.
Several limitations of our study need to be mentioned. The historical and observational nature of the study allows us to establish associations, but not causal relationships, between iron levels and outcomes. Our study sample was limited to male patients from a single medical center; hence, our results may not apply to the larger population with NDD-CKD. The enrollment of patients over an extended period of time in our study makes it possible that changing medical practices could have affected patient outcomes differently based on the time of enrollment. Similarly, the different baseline comorbidity characteristics of patients with different levels of iron markers could induce a bias related to different medical indications and hence influence outcomes independent of iron stores. We addressed these concerns by assessing the use of several medical interventions that are commonly applied in patients with CKD and that have undergone secular changes during the past 2 decades (such as ACEIs/ARBs, statins, or activated vitamin D products) and found no differences that could have indicated substantial discrepancies in the medical care delivered to patients with different levels of iron markers. We used single baseline values of the predictor, which could have biased our results because of the inherent variability of the parameters used. The lack of data on subsequent use of iron supplementation or erythropoiesis stimulating agents in our study population makes it possible that the outcomes associated with iron levels could be due to medications used in response to such levels. Lower iron levels have been associated with higher mortality independent of iron administration in dialysis patients (in whom iron products are more commonly used than in NDD-CKD), (28, 29) but the results of such studies cannot be extrapolated to our patient population.
Conclusions
Lower serum ISAT level is associated with higher mortality, and higher ISAT with more pronounced progression of kidney disease in NDD-CKD, but the latter association was only observed in patients who had evidence of malnutrition or inflammation. The association between serum ferritin and mortality appears weak and limited to a subset of patients in whom the utility of serum ferritin as a sensitive marker of iron stores is questionable. Because serum ISAT and ferritin levels are often used to make decisions about iron replacement therapy, the clinical and public health implications of our findings may be quite significant, indicating potential benefits (lower mortality), although an acceleration of CKD progression was also noted. It is paramount that prospective clinical trials of iron supplementation are undertaken with proper safeguards in place to delineate the boundaries of benefit and safety with such therapy in patients with NDD-CKD.
